E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Type 2 Diabetes Mellitus |
Diabetes Mellitus tipo 2 |
|
E.1.1.1 | Medical condition in easily understood language |
Type 2 Diabetes Mellitus |
Diabetes Mellitus tipo 2 |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Nutritional and Metabolic Diseases [C18] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The aim of the study is to evaluate the effect of treatment with empagliflozin 10 mg daily, on renal and systemic inflammation parameters, in patients with type 2 diabetes mellitus and ischemic heart disease at 6 months of treatment. |
El objetivo del estudio es evaluar el efecto del tratamiento con empagliflozina 10 mg al día, sobre parámetros de inflamación a nivel renal y sistémicos,en pacientes con diabetes mellitus tipo 2 y cardiopatía isquémica a los 6 meses de tratamiento. |
|
E.2.2 | Secondary objectives of the trial |
1. To evaluate the effect of empagliflozin treatment on renal and systemic inflammation parameters (IL- &, TNF alpha) in patients with type 2 diabetes mellitus with ischemic heart disease at 3 months of treatment.
2. Study the general situation of the patient including concomitant medication and morbidity.
3. Evaluate the continuity of treatment according to the appearance of adverse effects.
4. To evaluate specifically the appearance of hypoglycemia and its degree of severity. |
1.Evaluar el efecto del tratamiento con empagliflozina sobre parámetros de inflamación a nivel renal y sistémicos (IL-&, TNF alfa) en pacientes con diabetes mellitus tipo 2 con cardiopatía isquémica a los 3 meses de tratamiento.
2.Estudiar la situación general del paciente incluyendo la medicación concomitante y la morbilidad.
3.Evaluar la continuidad del tratamiento en función de la aparición de efectos adversos.
4.Evaluar específicamente la aparición de hipoglucemias y su grado de severidad.
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Patients diagnosed with type 2 DM with poor metabolic control (glycosylated hemoglobin> 6.5%)
2. Patients who have suffered an acute myocardial infarction or who have undergone a coronary revascularization procedure within 30 days prior to the start of the study.
3. Over 18 and under 85
4. Treatment with any hypoglycaemia including insulin.
5. Left ventricular ejection fraction preserved (LVEF> 40%)
6. Patients who have signed their consent to participate in the study |
1. Pacientes diagnosticados de DM tipo 2 con mal control metabólico (Hemoglobina glicosilada > 6,5 %)
2. Pacientes que hayan sufrido un infarto agudo de miocardio o que hayan sido sometidos a un procedimiento de revascularizaciíon coronaria en los 30 días previos al inicio del estudio.
3. Mayores de 18 y menores de 85 años
4. Tratamiento con cualquier hipoglucemiante incluida insulina.
5. Fracción de eyección del ventrículo izquierdo conservada (FEVI > 40 %)
6. Pacientes que hayan firmado su consentimiento para participar en el estudio
|
|
E.4 | Principal exclusion criteria |
1. Patients with type 1 DM.
2. Previous or current treatment with an SGLT2 inhibitor.
3. Creatinine clearance <60 ml / min / 1.73m2. |
1. Pacientes con DM tipo 1.
2. Tratamiento previo o actual con un inhibidor de SGLT2.
3. Aclaramiento de creatinina < 60 ml/min/1.73m2.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Main variable: Inflammatory activity determined by PCR, VSG, homocysteine, high sensitivity PCR, IL-6, IL-10, TNF alpha, MCP-1, TGF beta, CTGF, Endothelin 1, angiotensin 2. |
Variable Principal: Actividad inflamatoria determinada mediante PCR, VSG, homocisteina, PCR alta sensibilidad, IL-6, IL -10, TNF alfa, MCP-1, TGF beta, CTGF, Endotelina 1, angiotensina 2. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
1. General: Age, sex, height, weight, BMI, time of evolution of DM2, previous macrovascular complications, microvascular complications, blood pressure, heart rate.
2. Pharmacological: hypoglycaemic (including insulin), lipid-lowering, antihypertensive, antiplatelet, anticoagulants.
3. Hematological: hemoglobin, hematocrit
4. Lipid profile: total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides
5. Cardio-renal: Nt-ProBNP, Cr, urea, proteinuria (albumin / creatinine index), sodium and potassium in urine. Plastic and urinary osmolarity.
6. Endocrinological: fasting glucose, HbA1c, peptide c, ketone bodies in urine, ketonemia. Venous gasometry, severe hypoglycemia insulin?
7. Markers of oxidative stress: oxidant capacity in urine. |
1.Generales: Edad, sexo, talla, peso, IMC, tiempo de evolución de la DM2, complicaciones macrovasculares previas, complicaciones microvasculares, tensión arterial, frecuencia cardiaca.
2.Farmacológicos: hipoglucemiantes (incluido insulina), hipolipemiantes, antihipertensivos, antiagregantes, anticoagulantes.
3.Hematológicos: hemoglobina, hematocrito
4.Perfil lipídico: colesterol total, LDL colesterol, HDL colesterol, triglicéridos
5.Cardio-renales: Nt-ProBNP, Cr, urea, proteinuria (índice albúmina/creatinina), sodio y potasio en orina. Osmolaridad plamática y urinaria.
6.Endocrinológicos: glucosa en ayunas, HbA1c, péptido c, cuerpos cetónicos en orina, cetonemia. Gasometría venosa, hipoglucemias graves ¿insulina?
7.Marcadores de estrés oxidativo: capacidad oxidante en orina.
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | No |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
Otro tratamiento para la diabetes mellitus tipo 2 de acuerdo a la práctica clínica habitual |
Other Type 2 diabetes mellitus treatment according to usual clinical practice |
|
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
LVLS |
Última visita programada del último sujeto incluido |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | 24 |
E.8.9.1 | In the Member State concerned days | |